Tenet Healthcare Corporation stocks have been trading up by 18.08 percent following highly positive coverage of its strong earnings performance.
Click Here for a Millionaire's POV on Trading THC
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Market Insights For THC Traders
- Q2 2026 adjusted EPS of $6.12 crushed the $4.26 consensus on $5.63B revenue, helped by strong same-store growth, higher-acuity mix, and tight cost control.
- Management raised FY26 adjusted EPS guidance to $20.30-$21.69 and lifted revenue, EBITDA, and free cash flow targets, resetting Street expectations higher.
- Buyback firepower jumped with a $2B increase in authorization, leaving $2.13B available after $1.04B of repurchases last quarter.
- Wells Fargo, Barclays, BofA, and Guggenheim all sit on positive ratings for THC, even as some trim targets on sector-wide hospital multiple pressure.
- Recent price action pushed shares into the mid-$230s, reflecting a strong reaction to the earnings beat and guidance raise.
Weekly Update Jul 20 – Jul 24, 2026: On Friday, July 24, 2026 Tenet Healthcare Corporation stock [NYSE: THC] is trending up by 18.08%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Tenet Healthcare sits in the upper tier of U.S. provider platforms with a compelling profitability and FCF profile versus peers. EBIT margin of 18.6% and EBITDA margin of 22.8% are meaningfully above large hospital comps, while ROE near 38–48% and ROIC ~10–18% underscore strong capital efficiency, aided by leverage. The stock trades at ~9x earnings and 0.72x sales, with FCF yield implied by ~2.4x cash flow and 2.5x P/FCF highly attractive despite 2.74x debt-to-equity and 6.5x leverage.
Technically, THC is in a powerful bullish phase. The weekly progression from ~$194 to ~$234, including a large-range breakout day (high $233–235) on heavy volume, confirms a strong uptrend and successful post-earnings repricing. Intraday 5‑minute action shows persistent bid support rather than mean reversion, consistent with institutional accumulation. Key actionable level: $224 (prior breakout and weekly close) is now decisive support; above that, momentum traders can buy pullbacks with tight stops just below $220.
More Breaking News
- Digital Realty Trust Jumps As Q2 Beat Fuels Guidance Hike
- MOBX Stock Dips As Traders Focus On Weak Cash Position
- OTLK Stock Slips After Regaining Nasdaq Compliance
- SXT Stock Climbs As Dividend And Analyst Views Shape Trading
Fundamentally and sentiment-wise, the setup is unequivocally positive. Q2 2026 delivered a major beat (EPS $6.12 vs $4.26 consensus) and guidance reset (FY26 EPS $20.30–21.69) that outpaces most Healthcare Providers & Services peers and the broader Healthcare sector. Strength in hospital margins, ambulatory growth, and a $2B buyback expansion support multiple expansion. I see upside toward $245–255 near term, with support at $224 and secondary support around $210.
Quick Financial Overview
Tenet Healthcare Corporation just printed the kind of quarter that gets traders’ attention. Q2 2026 adjusted EPS came in at $6.12 versus $4.26 expected and $4.02 a year ago, on revenue of $5.63B versus $5.44B consensus. Management highlighted higher same-facility revenue, stronger hospital margins, and solid ambulatory performance, which lines up with profitability ratios that already looked strong: EBIT margin near 18.6% and EBITDA margin around 22.8%.
On the cash side, the latest report shows operating cash flow of about $1.64B and free cash flow of roughly $1.46B for the quarter, a powerful backdrop for the expanded repurchase plan. The balance sheet is still highly leveraged, with total debt to equity around 2.74 and interest coverage of 5.9, but returns are robust: return on equity is roughly 48.5% with return on capital in the mid‑teens. A P/E near 9.2 and price-to-sales around 0.72 keep the valuation looking undemanding relative to that earnings power.
The tape is confirming the story for now. Weekly data show THC ripping from the high‑$190s into the mid‑$230s, with the 2026/07/23 close near $224.01 and a follow‑through push to about $234.21 on 2026/07/24. Intraday on that latest session, the stock traded as high as roughly $246.56 before closing off the highs in the low‑$230s, which tells you there was profit-taking after an initial earnings spike but buyers were still willing to support pullbacks.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.